Companies · Biotechnology

Myotherix, Inc.

Emeryville · Biotechnology

Diligence memoA one-page analyst read on Myotherix, Inc. — recommendation, valuation, rhythm, risks.
$9.4M
Total raised · real
3
Rounds
15.9×
Latest step-up
Top 46%
Sector rank · raised
Series A
Latest stage · inferred · Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Myotherix, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.36× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
  • Within the normal band (136% of peer median) for its niche.
Dormant
  • Last raise 9.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Myotherix, Inc. is one of 4291 Biotechnology companies tracked from Emeryville. By capital raised it ranks mid-pack (ahead of 55% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
15
Investors (latest)
2013
Year incorporated
2017-02-14
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2015-06-24 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2015Pre-Seed · 2016-09-12 Raised $500K (real) Modeled valuation $28M (est)$500K$28MPre-Seed2016Series A · 2017-02-14 Raised $7.9M (real) Modeled valuation $287M (est)$7.9M$287MSeries A2017+$500K+$7.9MCumulative $9.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2015
Pre-Seed extension$500K · 2016
Series A$7.9M · 2017no Seed on file

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$286.7M
Base estimate est.
$8.7M
Conservative case
$1.6B
Upside case
$36.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $55.2M · 2015-06-242015Pre-Seed · modeled $27.6M · 2016-09-12Series A · modeled $286.7M · 2017-02-142017
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
9.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$5.7M/yr
Capital velocity
11.0 yr
On record since
2015
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.3× above median
This company$9.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.5× above median
This company$7.9M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 4.5× above median
This company$286.7M
Sector median$64.2M

Raised more than 55% of sector peers (real $). Modeled value above 76% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #47 of 157.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Myotherix, Inc. (this company) Raised $9.4M · modeled $286.7M (est)Myotherix, Inc.
CompanyStageRaised · realValue · estvs peer med.
Cynvec LLCSeries A$17.4M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Myotherix, Inc. this companySeries A$9.4M$286.7M1.36×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2015-06-24$5.6M$55.2M85%
Pre-Seed$500K2016-09-12$2.8M$27.6M85%
Series A$7.9M2017-02-14$36.0M$286.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2015-06-24
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$500K2016-09-12
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  3. Series A$7.9M2017-02-14
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 15.9× larger than the prior — scaling up.
    • 15 investors on this round.
Intelligence
2017 ~Q4
Modeled next raise · ~10mo cadence
$23.8M
Modeled next size est.range $15.5M$38.1M
15.9×
Last step-up
$5.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael Kelly10 other2015-06
Mark De Souza9 other2015-06
Mark P. De Souza6 other2017-02
Jak Knowles3 other2016-09
Michael P Kelly2 other2017-02
Babar P Ghias2017-02
Jak P Knowles2017-02
John Kincaid2015-06
John P Kincaid2017-02
Registry & provenance

Myotherix, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1647149
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
FlightPath Biosciences, Inc.BiotechnologySeries A$9.6M$82.3Mnetwork2 shared operators · same sector · same stage
PellePharm, Inc.BiotechnologySeries A$19.6M$271.1Mnetwork1 shared operator · same sector · same stage
FibRx Derm, Inc.BiotechnologySeries A$4.2M$151.8Mnetwork1 shared operator · same sector · same stage
Phoenicis Therapeutics, Inc.PharmaceuticalsSeries A$23.8M$38.6Mnetwork2 shared operators · same stage
Paragon Biosciences Evozyne Capital, LLCBiotechnologySeries A$9.5M$342.5Msame sector · same stage
Hemosphere, Inc.BiotechnologySeries A$9.3M$337.9Msame sector · same stage
MEC Dynamics CorpBiotechnologySeries A$9.5M$345.2Msame sector · same stage
Redpin Therapeutics, Inc.BiotechnologySeries A$9.3M$281.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Myogenica Inc.BiotechnologyPre-Seed$2.0M88%
Mitotherapeutix, LLCBiotechnologySeed$131.8M87%
Myodenovo Inc.BiotechnologyPre-Seed$1.2M87%
Imvax, Inc.BiotechnologySeries D+$4.6B87%
Myrtelle Inc.BiotechnologySeries B$117.0M87%
Amunix Pharmaceuticals, Inc.BiotechnologySeries D+$3.9B86%
Mytide Therapeutics, Inc.BiotechnologySeries A$12.7M86%
Imbria Pharmaceuticals, Inc.BiotechnologySeries C$405.5M85%
Frequently asked
How much funding has Myotherix, Inc. raised?
Myotherix, Inc. has raised approximately $9.4M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Myotherix, Inc.'s estimated valuation?
Provath's modeled valuation for Myotherix, Inc. is approximately $286.7M (modeled range $8.7M–$1.6B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Myotherix, Inc. at?
Myotherix, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Feb 14.
What does Myotherix, Inc. do and where is it based?
Myotherix, Inc. operates in the Biotechnology sector, based in Emeryville.
Explore related

See where Myotherix, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Myotherix, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.